EGFR-Mutant Non-Small Cell Lung Cancer | Market Intelligence

Description

List of Tables

Nowhere does EGFR-mutant lung cancer matter more than in East Asia, and Japan sits at the center of that epidemiology: among never-smoker adenocarcinoma patients, EGFR mutation is the dominant driver, which makes genotype-directed therapy the default architecture of Japanese thoracic oncology rather than a niche. The country that produced the IPASS-era insights and WJTOG trial culture now runs the world's most saturated EGFR treatment paradigm - osimertinib as anchor, a first-line intensification debate on top of it, and a post-progression landscape where sequencing choices multiply every year.

The tension is escalation versus restraint. AstraZeneca's Tagrisso franchise built the modern standard, and the FLAURA2 and ADAURA programs pushed osimertinib into combination first-line use and adjuvant treatment after resection. Johnson & Johnson's Rybrevant-plus-lazertinib MARIPOSA regimen now contests first-line outright, carrying an efficacy argument against a tolerability and logistics burden that Japanese physicians weigh differently than Western ones. Meanwhile a third-generation TKI diaspora - aumolertinib, furmonertinib - and exon-20 agents from Dizal and the legacy of Takeda's withdrawn Exkivity reshape the edges. Underneath the drug contest sits a diagnostic economy: every sequencing decision depends on testing breadth, turnaround, and re-biopsy practice that Japan's NGS reimbursement rules only partly reward.

This report maps EGFR-mutant NSCLC in Japan from diagnosis through lines of therapy. It profiles the approved armamentarium - first-generation erlotinib and gefitinib heritage, afatinib, dacomitinib, osimertinib, and the amivantamab combinations - with their pivotal programs and Japanese label histories, then walks the pipeline: MARIPOSA extensions, furmonertinib's global development through ArriVent, sunvozertinib, and resistance-directed strategies. Chapters cover re-biopsy and liquid-biopsy practice, adjuvant and stage III positioning after ADAURA and LAURA, and the sequencing conventions Japanese guidelines are still digesting.

The report serves thoracic-oncology BD teams, diagnostics firms sizing the testing attach, investors tracking the Tagrisso franchise and its challengers, and medical-affairs teams preparing Japan strategy. It delivers program-level and practice-level detail calibrated to how Japanese thoracic oncology actually operates.

Scope and Coverage: The report covers EGFR-mutant NSCLC epidemiology, diagnostics, approved therapies, pipeline agents, and sequencing practice in Japan across adjuvant, stage III, and metastatic settings. It profiles AstraZeneca, Johnson & Johnson, Boehringer Ingelheim, Pfizer, Roche/Chugai, Takeda, ArriVent, Allist, Hansoh, Dizal, and BeiGene, and addresses testing economics and guideline evolution.

Report Highlights:

Maps Japan's EGFR epidemiology and the testing infrastructure that gates targeted care
Profiles the approved TKI armamentarium with pivotal programs and Japanese labels
Analyzes the first-line contest between osimertinib-based regimens and MARIPOSA
Covers adjuvant and stage III positioning following ADAURA and LAURA
Walks the pipeline: furmonertinib, sunvozertinib, and resistance-directed strategies
Addresses re-biopsy, liquid biopsy, and the diagnostic attach opportunity

Product Code: JPH-033

Table of Content

1. Executive Summary

2. EGFR-Mutant Non-Small Cell Lung Cancer: Overview and Clinical Background

3. Epidemiology and Patient Population: US, EU5, Japan, and China

4. Current Treatment Landscape and Standard of Care

5. Pipeline and Development Activity

6. Regulatory Pathways: FDA, EMA, PMDA, and NMPA Considerations

7. Reimbursement and Pricing Analysis with a Focus on Japan's NHI System

8. Competitive Landscape and Key Companies

9. Unmet Needs and Commercial Opportunities in Japan

10. Appendix: Methodology and Sources

Companies Mentioned

AstraZeneca (UK) - Tagrisso (osimertinib); standard of care in EGFR-mutant NSCLC
Johnson & Johnson (US) - Rybrevant (amivantamab) plus lazertinib MARIPOSA regimen
Chugai (JP) - Japan commercialization of Roche oncology including legacy EGFR agents
Takeda (JP) - Exkivity (mobocertinib) legacy; Japan-originated EGFR program
Pfizer (US) - Vizimpro and legacy EGFR portfolio
Boehringer Ingelheim (DE) - Gilotrif (afatinib) second-generation EGFR TKI
Roche (CH) - Tarceva (erlotinib) legacy first-generation TKI
ArriVent BioPharma (US) - furmonertinib global rights outside China
BeiGene (CN) - China oncology portfolio with EGFR exposure
Hansoh Pharmaceutical (CN) - aumolertinib third-generation EGFR TKI
Dizal (CN) - sunvozertinib EGFR exon 20 inhibitor
Allist Pharmaceuticals (CN) - furmonertinib originator

Product Code: JPH-033

List of Tables

Table 1. EGFR Mutation Biology: Sensitizing, Exon 20, and Resistance Alterations
Table 2. EGFR-Mutant NSCLC Epidemiology in Japan: Never-Smoker Adenocarcinoma Context
Table 3. EGFR Testing Landscape in Japan: PCR, NGS Panels, and Liquid Biopsy
Table 4. Reimbursed Companion Diagnostics for EGFR Therapy Selection
Table 5. Testing Turnaround, Re-Biopsy Practice, and Tissue-Economy Challenges
Table 6. First-Generation TKI Heritage: Gefitinib and Erlotinib in Japanese Practice
Table 7. Gilotrif (Afatinib): Program Profile and Japanese Positioning
Table 8. Vizimpro (Dacomitinib): ARCHER Program Context
Table 9. Tagrisso (Osimertinib): Mechanism and Japanese Franchise Structure
Table 10. FLAURA Program: First-Line Osimertinib Monotherapy Evidence Framework
Table 11. FLAURA2: Osimertinib Plus Chemotherapy Design and Positioning Questions
Table 12. ADAURA: Adjuvant Osimertinib Program and Surgical-Pathway Integration
Table 13. LAURA: Stage III Consolidation Osimertinib After Chemoradiation
Table 14. Rybrevant (Amivantamab): Bispecific Mechanism and Administration Burden
Table 15. MARIPOSA: Amivantamab Plus Lazertinib First-Line Program Design
Table 16. MARIPOSA-2: Post-Osimertinib Combination Strategy
Table 17. Lazertinib: Leclaza Heritage and Combination Role
Table 18. Exkivity (Mobocertinib): Takeda's Exon 20 Program and Withdrawal Lessons
Table 19. Sunvozertinib (Dizal): Exon 20 Program Design
Table 20. Furmonertinib: Allist Origin and ArriVent Global Development
Table 21. Aumolertinib (Hansoh): Third-Generation TKI Program and Japan Relevance
Table 22. BeiGene EGFR-Adjacent Portfolio Context
Table 23. Resistance Mechanism Taxonomy After Third-Generation TKIs
Table 24. MET-Amplification Strategies in Post-Osimertinib Disease
Table 25. HER3-DXd and ADC Approaches in Post-TKI Populations
Table 26. Post-Progression Biopsy and Genotyping Practice in Japan
Table 27. Sequencing Conventions in Japanese Guidelines for EGFR-Mutant NSCLC
Table 28. Stage-by-Stage Treatment Architecture: Resectable, Stage III, and Metastatic
Table 29. Surgical and Adjuvant Workflow Integration of Genotype-Directed Therapy
Table 30. CNS Disease Management in EGFR-Mutant NSCLC
Table 31. Oligoprogression and Local-Therapy Practices in Japan
Table 32. Tolerability and Quality-of-Life Considerations Across Regimens
Table 33. NHI Pricing and Cost-Effectiveness Treatment of EGFR Therapies
Table 34. Combination Regimen Logistics: Infusion, Dermatology, and VTE Management
Table 35. Chugai and Roche Legacy EGFR Portfolio Roles in Japan
Table 36. Pfizer EGFR Portfolio Position in the Japanese Market
Table 37. Competitive Positioning Matrix: EGFR Regimens by Setting and Line
Table 38. China Third-Generation TKI Diaspora and Japan Entry Prospects
Table 39. Trial-Enrollment Competition in EGFR-Mutant Populations in Asia
Table 40. Biomarker-Lab Economics of EGFR Testing Breadth
Table 41. Scenario Framework: First-Line Standard-of-Care Paths
Table 42. Risk Register: Resistance Evolution, Guideline Shifts, and Pricing Pressure
Table 43. Indicator Dashboard for EGFR Franchise Monitoring
Table 44. Due-Diligence Checklist for EGFR-Asset Licensing
Table 45. Diagnostic Attach Sizing Framework for EGFR Testing
Table 46. Stakeholder Position Map: Societies, Payers, and Sponsors
Table 47. Real-World Evidence Sources for EGFR-Mutant NSCLC in Japan
Table 48. Patient Advocacy and Access Considerations in Targeted Lung Care
Table 49. Horizon Scan: Fourth-Generation EGFR Inhibitors and Degraders
Table 50. Analytical Appendix: Trial Registries, Guidelines, and Claims Data Sources

List of Figures

Figure 1. EGFR Alteration Taxonomy Diagram
Figure 2. Japan EGFR Epidemiology Framework
Figure 3. EGFR Testing Pathway: Tissue, NGS, and Liquid Biopsy
Figure 4. Companion Diagnostic Attach Map
Figure 5. Re-Biopsy and Tissue-Economy Workflow
Figure 6. First-Generation TKI Heritage Timeline
Figure 7. Afatinib and Dacomitinib Program Schematics
Figure 8. Osimertinib Franchise Architecture
Figure 9. FLAURA and FLAURA2 Design Schematics
Figure 10. ADAURA Adjuvant Pathway Integration
Figure 11. LAURA Stage III Positioning Diagram
Figure 12. Amivantamab Mechanism and Administration Flow
Figure 13. MARIPOSA Program Family Tree
Figure 14. Lazertinib Combination Role Diagram
Figure 15. Exkivity Program and Withdrawal Lessons Framework
Figure 16. Sunvozertinib and Furmonertinib Program Maps
Figure 17. Aumolertinib Program Positioning
Figure 18. Resistance Mechanism Map After Third-Generation TKIs
Figure 19. MET-Amplification Strategy Diagram
Figure 20. ADC Approaches in Post-TKI Disease
Figure 21. Post-Progression Genotyping Practice Flow
Figure 22. Japanese Guideline Sequencing Map
Figure 23. Stage-by-Stage Treatment Architecture
Figure 24. Surgical-Pathway Integration of Adjuvant Therapy
Figure 25. CNS Management Framework
Figure 26. Oligoprogression Local-Therapy Practice Diagram
Figure 27. Tolerability Comparison Framework
Figure 28. NHI Pricing Pathway for EGFR Therapies
Figure 29. Combination Logistics Map: Infusion, Dermatology, VTE
Figure 30. Chugai/Roche and Pfizer Portfolio Positioning
Figure 31. Competitive Positioning Map by Setting and Line
Figure 32. China TKI Diaspora Entry Pathways
Figure 33. Enrollment Competition Dynamics in Asia
Figure 34. Biomarker-Lab Economics Diagram
Figure 35. Scenario Tree: First-Line Standard Paths
Figure 36. Risk Map: Resistance, Guidelines, and Pricing
Figure 37. EGFR Franchise Monitoring Dashboard
Figure 38. Licensing Due-Diligence Flow
Figure 39. Diagnostic Attach Sizing Framework Diagram
Figure 40. Stakeholder Position Map
Figure 41. Real-World Evidence Source Map
Figure 42. Patient Journey from Diagnosis Through Lines of Therapy
Figure 43. Physician Decision Points in Post-Osimertinib Care
Figure 44. Clinical Trial Network Footprints in Japanese Thoracic Oncology
Figure 45. Fourth-Generation Inhibitor and Degrader Horizon Scan
Figure 46. Investor KPI Dashboard for the EGFR Theme
Figure 47. Sponsor Positioning Options Around the Tagrisso Standard
Figure 48. Testing-Breadth Policy Levers in NGS Reimbursement
Figure 49. Synthesis: What Decides the Next EGFR Standard in Japan
Figure 50. Report Roadmap: Chapter Linkages to Reader Decisions

EGFR-Mutant Non-Small Cell Lung Cancer | Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. EGFR-Mutant Non-Small Cell Lung Cancer: Overview and Clinical Background

3. Epidemiology and Patient Population: US, EU5, Japan, and China

4. Current Treatment Landscape and Standard of Care

5. Pipeline and Development Activity

6. Regulatory Pathways: FDA, EMA, PMDA, and NMPA Considerations

7. Reimbursement and Pricing Analysis with a Focus on Japan's NHI System

8. Competitive Landscape and Key Companies

9. Unmet Needs and Commercial Opportunities in Japan

10. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures